The published research behind our approach.

The research presented here represents the published scientific literature that informs our approach. This page presents the evidence for human-origin probiotics, high-potency dosing, gut terrain preparation, and phased microbiome restoration — the four pillars behind our formulation and protocol. Every citation links to PubMed or the originating journal.

These papers were selected for their direct relevance to the principles underlying Progurt's formulation and protocol. None are Progurt-specific. All are publicly available through PubMed or their respective journals.

12 peer-reviewed sources behind the formulation & protocol
Human origin Terrain Dosing Protocol

Vemuri et al., 2018 Human vs plant vs dairy origin strains
Lugli et al., 2024 Human-origin Bifidobacterium adhesion advantage
Zhang et al., 2024 Host-specificity in probiotic response
Krumbeck et al., 2018 Gut-native strains colonise better
Zmora et al., 2018 Gut environment controls probiotic colonisation
Sood et al., 2009 High-dose probiotic remission in active UC
Gionchetti et al., 2000 85% remission maintenance with high-dose probiotic
Benech et al., 2024 Gut preparation determines transplant outcome
Sinopoulou et al., 2024 Prebiotics worsen symptoms in IBD
Zhao et al., 2025 Lactoferrin and barrier integrity
Yan et al., 2026 Mineral status and gut barrier function
McFarland et al., 2018 Strain-specificity and disease-specificity

A human origin strain Lactobacillus acidophilus DDS-1 exhibits superior in vitro probiotic efficacy in comparison to plant or dairy origin probiotics

Vemuri et al., 2018 · International Journal of Medical Sciences
Head-to-head comparison of human-origin, plant-origin, and dairy-origin probiotic strains under identical conditions. The human-origin strain demonstrated superior gastrointestinal survival, effective adhesion to human intestinal cells, and the strongest immunomodulatory response — significantly upregulating anti-inflammatory IL-10 and downregulating pro-inflammatory TNF-alpha.
Read on PubMed

Characterization of a Bifidobacterium animalis subsp. lactis reference strain based on ecology and transcriptomics

Lugli et al., 2024 · Applied and Environmental Microbiology
A human-origin Bifidobacterium strain demonstrated significantly greater adhesion to intestinal cells than an industrial probiotic strain of the same species, with 291 genes upregulated for direct host interaction.
Read on PubMed

Lactobacillus rhamnosus GG triggers intestinal epithelium injury in zebrafish revealing host dependent beneficial effects

Zhang et al., 2024 · iMeta
A well-characterised human probiotic caused adverse intestinal effects in a non-human host through species-specific immune receptor activation, demonstrating that the probiotic-host relationship is not interchangeable across species.
Read on PubMed

Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics

Krumbeck et al., 2018 · Microbiome
Randomised, double-blind, placebo-controlled trial in humans. A gut-native Bifidobacterium strain achieved significantly higher intestinal cell numbers than a widely used commercial strain. Being native to the human gut had a larger effect on ecological performance than providing prebiotic substrate alongside the probiotic.
Read on PubMed

Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features

Zmora et al., 2018 · Cell
Researchers administered a multi-strain probiotic and performed endoscopies to measure actual mucosal colonisation. The existing gut microbiome actively resisted probiotic colonisation, and baseline gut composition predicted who would respond. Stool detection of probiotics did not correlate with mucosal colonisation — most studies overestimate probiotic engraftment by measuring stool only.
Read on PubMed

Induction of remission in patients with mild-to-moderately active ulcerative colitis using a high-dose multi-strain probiotic

Sood et al., 2009 · Clinical Gastroenterology and Hepatology
Multicentre, randomised, double-blind, placebo-controlled trial (n=147). A high-dose multi-strain probiotic at 3.6 trillion CFU twice daily (7.2 trillion CFU/day total) achieved 42.9% remission compared to 15.7% on placebo at 12 weeks (P < .001). Safety profile equivalent to placebo.
Read on PubMed

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

Gionchetti et al., 2000 · Gastroenterology
Landmark randomised controlled trial (n=40). A high-dose multi-strain probiotic at approximately 3 trillion bacteria per day maintained remission in 85% of patients at nine months, compared to 0% on placebo (P < .001). One of the most dramatic results in probiotic medicine.
Read on PubMed

Impact of clinical and pharmacological parameters on faecal microbiota transplantation outcome in Clostridioides difficile infections

Benech et al., 2024 · Alimentary Pharmacology & Therapeutics
National survey of 658 FMT procedures across 17 centres. Insufficient bowel preparation was associated with a 5.5-fold increase in disease recurrence (OR: 5.47). Partial product retention was associated with a nearly 10-fold increase in failure (OR: 9.97). The preparation phase was determinative.
Read on PubMed

Prebiotics for induction and maintenance of remission in ulcerative colitis

Sinopoulou et al., 2024 · Cochrane Database of Systematic Reviews
Cochrane systematic review (9 RCTs, 445 participants). Prebiotic supplementation in patients with ulcerative colitis led to significantly more total adverse events than placebo (77% vs 46%; RR 1.68). No clear clinical benefit for remission.
Read on PubMed

Assessment of recombinant human lactoferrin using intestinal barrier co-culture

Zhao et al., 2025 · Wei Sheng Yan Jiu
In an intestinal barrier co-culture model, recombinant human lactoferrin significantly reduced inflammatory markers (IL-1beta, IL-8, CCL2), increased transmembrane resistance, and reduced intestinal permeability, demonstrating barrier-protective effects independent of probiotic activity.
Read on PubMed

Nutritional trace elements influence the pathogenesis and resolution of inflammatory bowel disease

Yan et al., 2026 · Food & Function
Zinc deficiency was found to compromise intestinal barrier integrity and amplify inflammatory immune responses through the IL-23/Th17 axis. Magnesium maintained barrier function through the TRPM6 ion channel. Mineral status directly influences the gut environment in which probiotics must operate.
Read on PubMed

Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis

McFarland et al., 2018 · Frontiers in Medicine
Strong evidence that probiotic efficacy is both strain-specific and disease-specific. Reviews that pool different probiotic strains together produce misleading efficacy conclusions, supporting the case for carefully selected, targeted formulations over generic products.
Read on PubMed

The human gastrointestinal tract is not a single environment. The small intestine and large intestine differ in pH, oxygen levels, nutrient availability, and resident bacterial populations. Different bacterial genera have evolved to thrive in different regions. A formulation that targets only one zone leaves the rest unaddressed.

Progurt's formulation includes strains that are beneficial residents of the small intestine and strains that are beneficial residents of the large intestine, along with supportive organisms that contribute to the broader ecosystem. This is not a random collection. It is a deliberately constructed consortium — multiple genera, each selected for a specific ecological role.

Published research supports this approach. An open-label study evaluating a three-genus combination of Lactobacillus, Bifidobacterium, and Enterococcus species in irritable bowel syndrome reported a 74.3% effective rate at four weeks, with progressive improvement over the supplementation period. An umbrella meta-analysis across 35 meta-analyses of randomised controlled trials concluded that multi-strain probiotics were particularly effective for preventing necrotising enterocolitis in preterm infants, showing a stronger effect than single-strain preparations. Mechanistic research proposes complementary pathways through which multi-strain consortia may achieve superior outcomes: ecological niche complementation, enhanced immune modulation through broader induction of regulatory T cells, and a wider pathogen inhibition spectrum from multiple bacteriocins and competitive metabolites.

The evidence is nuanced — not every comparison favours multi-strain over single-strain in every context. But the principle is ecological: a diverse, multi-zone consortium adapted to the human gut is more resilient than any single organism, no matter how well-studied that organism may be.

The most direct parallel to Progurt's MEND Method in clinical practice is faecal microbiota transplantation. FMT is the most studied and most effective form of microbiome restoration available. Its protocols are instructive.

FMT does not begin with bacteria. It begins with preparation. Clinical protocols include bowel cleansing to reduce competing microbiota, assessment of recipient gut health, and optimisation of the intestinal environment. The therapeutic bacteria are introduced only after this preparation is complete. Post-transplant, clinicians recommend dietary modifications and prebiotic supplementation to sustain the newly established community.

A French national survey of 658 FMT procedures across 17 clinical centres found that insufficient bowel preparation was associated with a 5.5-fold increase in disease recurrence. Partial product retention was associated with a nearly 10-fold increase in failure. The preparation phase was not optional — it was determinative.

This phased logic directly informs the MEND sequence.

Mineralise draws from the same principle as the FMT preparation phase. Mineral supplementation, pH buffering, and hydration support create an intestinal environment capable of receiving and sustaining new bacterial populations. Research confirms that zinc is essential for barrier integrity, magnesium for motility and ion channel function, and adequate hydration for mucus layer maintenance.

Establish is informed by the transplant phase itself. One trillion CFU of human-origin bacteria per sachet are introduced into a prepared environment across multiple doses. Research on the existing gut microbiome shows it actively resists incoming bacteria through ecological competition — bile acid metabolism, nutrient competition, and spatial niche exclusion. Preparing the terrain reduces this resistance and creates open ecological niches for the incoming strains. In vitro research on live vs inactivated bacterial preparations confirms that actively metabolising organisms are required for pathogen inhibition in laboratory settings.

Nourish is informed by the post-transplant support phase. Prebiotics and lactoferrin are introduced after beneficial bacteria are established. The timing reflects a consistent finding across multiple systematic reviews: prebiotic supplementation in patients with active gut dysfunction frequently worsens symptoms rather than improving them. A Cochrane review found significantly more total adverse events with prebiotics than placebo in ulcerative colitis patients (77% vs 46%). A separate meta-analysis found that inulin-type fructans worsened flatulence in irritable bowel syndrome and other functional bowel disorders. Published research confirms that prebiotic effectiveness depends on the composition of existing microbiota — and that in dysbiotic conditions, fermentable substrates may be metabolised by the wrong organisms. You nourish the ecosystem only after the right organisms are in place. Lactoferrin, tested in intestinal barrier models, provides independent barrier support, reducing inflammatory markers and protecting epithelial integrity.

Defend is the long-term maintenance phase. Ongoing yogurt preparation using Progurt's incubator sustains the bacterial community. Enzyme support aids digestion and nutrient absorption. This phase prevents regression toward the dysbiotic baseline.

No published research has tested this exact four-phase sequence as a single protocol. What the literature does support — consistently, across multiple research groups and clinical contexts — is that phased microbiome restoration outperforms single-intervention approaches, that gut preparation determines probiotic success, and that prebiotic timing matters.

Progurt's formulation originates from the Japanese pharmaceutical probiotic tradition — a distinct category of clinically validated bacterial preparations with no direct equivalent in most Western markets.

In Japan, intestinal regulators (seicho-zai) are classified as pharmaceutical or quasi-pharmaceutical products, regulated with rigour that far exceeds the dietary supplement framework used in most Western countries. Strains must be individually characterised, safety must be documented through long-term clinical data, and manufacturing must meet exacting standards. This is fundamentally different from Western supplement regulation, where strain-level characterisation is rarely required.

The genera used in Progurt's formulation have accumulated decades of documented safety within this framework. Some have been in continuous clinical use for over a century — one preparation dating to 1917 has maintained an unbroken safety record across more than a hundred years of use. Genomic characterisation of probiotic strains within this lineage confirms the absence of key virulence determinants — including cytolysin, gelatinase, and enterococcal surface protein — that distinguish hospital-associated pathogenic lineages from commensal and probiotic strains. While some colonisation-associated genes are retained (as they are required for the probiotic to function), the antibiotic resistance markers and pathogenicity islands characteristic of clinical isolates are absent. Published safety reviews confirm that probiotic strains without these virulence traits pose no identified risk to immunocompetent individuals, though as with all probiotics, immunocompromised patients should consult their healthcare provider.

Progurt is sold as a food — but the science and standards behind it come from a tradition that held itself to a higher threshold long before the Western market began asking the right questions about probiotic quality.

Begin

Questions from practitioners.

If you're a healthcare practitioner seeking additional detail on our formulation, protocol, or the research behind our approach, we welcome direct enquiry. Some information we share publicly; some we reserve for professional channels.

Already a customer? Reorder your protocol